The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2018 | Chlormethine gel: opinion on potential approval and usage in Europe
Topical alkylating agents have proven beneficial in treating patients with mycosis fungoides (MF). Here, Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses this topic at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Prof. Baggot covers the access to chlormethine gel in France, and describes its potential in the treatment of early-stage MF as a stand-alone therapy, and in late-stage MF when used as an adjunct treatment.
